Despite a slowdown in sales as Lipitor becomes a generic drug, pharma giant Pfizer is still a very good buy, and a great play for your portfolio. More
Novartis
Recent Articles
Are Pharma’s ‘Good Old Days’ Gone Forever?
You bet they are: Patent losses, a higher bar for FDA approvals, and slew of smaller, nimbler rivals have reshaped the industry. More
5 Ways to Invest in Europe as the Debt Dust Cloud Settles
From pink sheets to leveraged ETFs -- and some safer means in between -- there are numerous opportunities for investors to play Europe. More
Aftermath of August’s Intraday Low
A week after the stock market formed its intraday low, the rebound is still shaky. For now, investors should be selective with new purchases. More
